Jukema JW, Van Neer NJ, Szarek M, Cobbaert C, Bittner VA, Schwertfeger M, Bhatt DL, Fazio S, Goodman SG, Harrington RA, Stevanovic I, White HD, Steg PG, Schwartz GG. Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome. Eur Heart J. 2026 Oct 26; 47(40):6008-6017.

Horiike A, Wakui H, Sugawara S, Minegishi Y, Tasaka S, Kusumoto S, Sakatani T, Suzuki H, Hosomi Y, Tambo Y, Shimokawa T, Ishida H, Miyauchi E, Naoki K, Fukuhara T, Mura E, Tsurui T, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Manabe R, Shimokawa M, Ohkuma R, Ariizumi H, Kubota Y, Hamada K, Takenoshita S, Ryu K, Sambe T, Inoue E, Wada S, Yoshimura K, Sagara H, Kobayashi S, Tsunoda T. Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with =50% PD-L1 Expression: A Nonrandomized Phase II Trial. Clin Cancer Res. 2026 Oct 15; 32(20):4571-4579.

Wingerchuk DM, Bennett JL, Berthele A, Clardy SL, Kim HJ, Nakahara J, de Sèze J, Kinoshita M, Sharma B, Uchida CL, Deeb Bou-Chahine R, Parks B, Allen K, Stankowski JN, Pittock SJ. Astrocytic and Axonal Injury Biomarkers in AQP4 Antibody-Positive NMOSD: Insights From PREVENT and CHAMPION-NMOSD. Neurol Neuroimmunol Neuroinflamm. 2026 Nov; 13(6):e200661.

Herold KC, Dayan CM, Chatenoud L, Gitelman SE, Sumnik Z, Simmons K, Szypowska A, Knecht LA, Niemoeller E, Rigby MR, Tian W, Hill R, Ramos EL. Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial. Diabetologia. 2026 Dec; 69(12):3501-3511.

Bentebibel SE, McGrail DJ, Kochat V, Arslan E, Abdel-Wahab R, Pazdrak B, Murthy R, Tahon NHM, Cho SN, Duose DY, Wani KM, Liu J, Haymaker C, Gomez JA, Sonnemann H, Katailiha AS, Nassif-Rausseo B, Rahim M, Li I, Mayer AT, Yang X, Hsu FJ, Zhang J, Johnson DH, Amaria RN, Glitza Oliva IC, Patel SP, Hwu P, Elsayes KM, Tawbi HA, Burks JK, Bernatchez C, Davies MA, Rai K, Lizée G, Ekmekcioglu S, Diab A. Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study. Cancer Discov. 2026 Sep 01; 16(9):1780-1800.

Vilaseca A, Bilodeau PA, Gakis G, Savransky A, Mahler Ferreira Oliveira J, Nguyen L, Hooshmand SI, Satyanarayan S, Moseley CE, Haley L, Roy-Hewitson C, Marrodan M, Casallas A, Manin A, Chen H, Hoshina Y, Grzezulkowska A, Carnero Contentti E, Galleguillos L, Upchurch M, Jackson-Tarlton CS, Chu-Yueh Guo J, Fabian M, Virupakshaiah A, Arrambide G, Caparó-Zamalloa C, Paterno R, Waubant E, Ordoñez Boschetti L, Correale J, Villa AM, Banwell B, Marignier R, Pittock SJ, Greenberg B, Bennett JL, Cho T, Clardy S, Solomon AJ, Kister I, Zamvil SS, Gelfand JM, Repovic P, Obeidat AZ, Blackburn K, Tenembaum S, Chen JJ, Sotirchos ES, Levy M, Flanagan EP, Murillo F, Syc-Mazurzek SB, Cacciaguerra L, Jiang M, da Silva Rezende NB, Wingerchuk DM, Horsman SE. Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol. 2026 Sep 01; 83(9):860-872.

Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep; 27(9):1094-1109.

Tung N, Zhao F, DeMichele A, Prat A, Winer EP, Wright JL, Recht A, Weiss AC, Tjoe JA, Feldman SM, Rocque GB, Smith ML, O'Sullivan CC, Sardesai SD, Tang SC, Modi S, Irvin WJ, Unni N, Battelli C, Bagegni N, Krie AK, George MA, Telli ML, Borges VF, D'Abreo N, Shah P, Villagrasa P, Badve S, Partridge AH, Miller KD, Carey LA, Wolff AC. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. J Clin Oncol. 2026 Oct 20; 44(30):2919-2928.

Gurrea-Rubio M, Sloan S, Chada A, Amarista CI, Maeda K, Campbell PL, Tsou PS, Cooney LA, Wicha MS, Fox DA. CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer. Biomolecules. 2026 Aug 17; 16(8).